Monogram (MGRM) holding gains after soaring following FDA nod for robotic surgical system
Shares of Monogram Technologies Inc. (NASDAQ:MGRM) rose 57% on March 17 after the FDA granted 510k clearance to the Monogram mBôs TKA System. The company expects the mBôs, a precision robotic surgical system, initially to be applied in knee replacement procedures.
Stryker Corporation’s (NYSE:SYK) Mako system remains the market leader in robotic surgery for knees. Rather than relying on the hand-guided cutting of the knee directed by the Mako system, the mBôs precisely places the surgical cut into the knee after modeling the locations of the relevant cartilage and bone. The mBôs significantly reduces the time a patient is in surgery, according to Monogram.
With a market cap of $125 million, Monogram likely will not threaten Stryker’s ($142 billion market cap) dominance in the near term but the FDA clearance opens the door to broad commercialization in the near term. Monogram wants to upgrade its current, FDA-cleared cutting system of the mBôs and to advance late-stage studies in the US and India prior to commercialization. Both actions are designed to strengthen the competitiveness of the mBôs system.
The autonomous cut offered by the mBôs clearly elevates robotic surgery to a higher level of precision. The use of robotic surgery is increasing across knee, hip and shoulder replacement procedures, all procedures where Monogram expects to compete. Monogram claims it can commercialize the system successfully via just 20 surgeons.
Monogram has kept its cash burn low and claims it will seek to increase the company’s value through its commercialization efforts. The FDA clearance, however, likely also creates multiple capital and partnership opportunities for Monogram to move the mBôs into the market.
When Biotech Currents issued a report on the mBôs system in November 2024, the company’s stock traded at $2.22 per share. At the close of trading on March 17, 2025, Monogram shares were priced at $3.67 per share after touching a high of $4.21 per share.
Biotech Aims To Win Over Surgeons With New Automated System Poised to Transform Knee Replacement Surgery
A small, ambitious medical technology company is stepping into the knee joint replacement market with a bold system designed to challenge an established industry leader. Their innovation introduces fully automated surgical cutting capabilities, eliminating the need for hand-guided incisions. By modeling the precise locations of cartilage and bone, the system ensures greater accuracy and reduces the time patients spend in surgery—a feature that’s likely to appeal to both efficiency-focused surgeons and cost-conscious payers.